ERBB2 and breast cancer: unveiled the findings of a phase III randomized open label study, revealing that for HER2-positive breast cancer patients who encountered a recurrence after undergoing a regimen involving anthracyclines, taxanes, and trastuzumab, the combination of lapatinib and capecitabine significantly prolonged the median progression time while reducing the risk of disease progression by 51% when compared to capecitabine alone (20).